MCID: CHN002
MIFTS: 36

Chancroid

Categories: Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Chancroid

MalaCards integrated aliases for Chancroid:

Name: Chancroid 12 75 53 55 44 15 33
Ulcus Molle, Skin 12
Chancroids 72

Classifications:



External Ids:

Disease Ontology 12 DOID:13778
ICD9CM 35 099.0
MeSH 44 D002602
SNOMED-CT 68 87429008
ICD10 33 A57
UMLS 72 C0007947

Summaries for Chancroid

NIH Rare Diseases : 53 Chancroid is a bacterial infection that is spread through sexual contact. It is caused by a type of bacteria called Haemophilus ducreyi. Chancroid is characterized by a small bump on the genital which becomes a painful ulcer. Men may have just one ulcer, but women often develop four or more. About half of the people who are infected with a chancroid will develop enlarged inguinal lymph nodes, the nodes located in the fold between the leg and the lower abdomen. In some cases, the nodes will break through the skin and cause draining abscesses. The swollen lymph nodes and abscesses are often called buboes. Chancroid infections can be treated with antibiotics, including azithromycin, ceftriaxone, ciprofloxacin, and erythromycin. Large lymph node swellings need to be drained, either with a needle or local surgery.

MalaCards based summary : Chancroid, also known as ulcus molle, skin, is related to syphilis and lymphogranuloma venereum. An important gene associated with Chancroid is CD36 (CD36 Molecule), and among its related pathways/superpathways are Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers and Hematopoietic cell lineage. The drugs Acyclovir and Anti-Infective Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, lymph node and testes.

Disease Ontology : 12 A primary bacterial infectious disease that is a sexually transmitted infection located in skin of the genitals, has material basis in Haemophilus ducreyi, which is transmitted by sexual contact. The infection has symptom painful and soft ulcers.

Wikipedia : 75 Chancroid (/'?a?kr??d/ SHANG-kroyd) is a bacterial sexually transmitted infection characterized by... more...

Related Diseases for Chancroid

Graphical network of the top 20 diseases related to Chancroid:



Diseases related to Chancroid

Symptoms & Phenotypes for Chancroid

Drugs & Therapeutics for Chancroid

DrugBank drugs 16 :

(show all 8)
# Drug Name Indication DrugBank ID
1 Acetyl sulfisoxazole Acute, recurrent or chronic urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) due to susceptible organisms (usually Escherichia coli, Klebsiella-Enterobacter, staphylococcus, Proteus mirabilis and, less frequently, Proteus vulgaris) in the absence of obstructive uropathy or foreign bodies [L2804] Meningococcal meningitis where the organism has been demonstrated to be susceptible. Haemophilus influenzae meningitis as adjunctive therapy with parenteral streptomycin [L2804] Meningococcal meningitis prophylaxis [L2804]. Acute otitis media due to Haemophilus influenzae when used concomitantly with adequate doses of penicillin or erythromycin (see appropriate labeling for prescribing information) [L2804]. Trachoma, inclusion conjunctivitis, nocardiosis, chancroid, toxoplasmosis as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum, when used as adjunctive therapy [L2804]. Currently, the increasing frequency of resistant organisms is a limitation of the usefulness of antibacterial agents including the sulfonamides, especially in the treatment of chronic and recurrent urinary tract infections [L2804]. DB14033
2 Azithromycin Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin [FDA label]. Azithromycin is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the microorganisms listed in the specific conditions below. Recommended dosages, duration of therapy and considerations for various patient populations may vary among these infections. Refer to the FDA label and "Indications" section of this drug entry for detailed information [FDA label]. **Adults**: Acute bacterial exacerbations of chronic obstructive pulmonary disease due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_ Acute bacterial sinusitis due to _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_ Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to _Staphylococcus aureus_, _Streptococcus pyogenes_, or _Streptococcus agalactiae_. Abscesses usually require surgical drainage. Urethritis and cervicitis due to _Chlamydia trachomatis_ or _Neisseria gonorrhoeae_. Genital ulcer disease in men due to _Haemophilus ducreyi_ (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. **Pediatric Patients** Acute otitis media caused by _Haemophilus influenzae_, _Moraxella catarrhalis_ or _Streptococcus pneumoniae_ Community-acquired pneumonia due to _Chlamydophila pneumoniae_, _Haemophilus influenzae_, _Mycoplasma pneumoniae_ or _Streptococcus pneumoniae_ in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by _Streptococcus pyogenes_ as an alternative to first-line therapy in individuals who cannot use first-line therapy. DB00207
3 Ceftriaxone For the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph DB01212
4 Doxycycline Doxycycline is indicated for the treatment of various infections by gram-positive and gram-negative bacteria, aerobes and anaerobes, as well other types of bacteria. A complete list of organisms is available in the FDA label and in the "indications" section of this drug entry [FDA label]. The following are some of the major infections that may be treated with doxycycline [FDA label]: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (ornithosis) caused by Chlamydia psittaci Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis Nongonococcal urethritis caused by Ureaplasma urealyticum Relapsing fever due to Borrelia recurrentis **A note regarding anti-microbial resistance** It is important to note that doxycycline is not the drug of choice in the treatment of any type of staphylococcal infection. Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracyclines. Therefore, tetracyclines such as doxycycline should not be used to treat streptococcal infections unless the microorganism has been demonstrated to be susceptible [FDA label]. DB00254
5 Erythromycin Erythromycin is indicated in the treatment of infections caused by susceptible strains of various bacteria.[L7261] The indications for erythromycin have been summarized by body system below: **Respiratory infections** Mild to moderate upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with appropriate doses of sulfonamides) can be treated with erythromycin.[L7261] Mild to moderate lower-respiratory tract infections due to susceptible strains of Streptococcus pneumoniae or Streptococcus pyogenes may also be treated. Erythromycin treats listeriosis caused by Listeria monocytogenes may also be treated with erythromycin.[L7261] Erythromycin is indicated to treat pertussis (whooping cough) caused by Bordetella pertussis. It is effective in eliminating the causative organism from the nasopharynx of infected individuals, rendering them noninfectious. Clinical studies suggest that erythromycin may aid in the prevention of pertussis infection for individuals who have been exposed to the bacteria.[L7261] Respiratory tract infections due to Mycoplasma pneumoniae may also be treated with erythromycin.[L7261] Despite the fact that no controlled clinical efficacy studies have been conducted to this date, in vitro and certain preliminary clinical study results indicate that erythromycin may be an effective treatment in Legionnaires’ Disease.[L7261] Finally, erythromycin is indicated to treat diphtheria and other infections due to Corynebacterium diphtheriae, as an adjunct to antitoxin, to prevent carrier status and to eradicate the organism in existing carriers.[L7261] In addition to the prevention of diphtheria, erythromycin can be used to prevent rheumatic fever in penicillin intolerant patients.[L7261] **Skin infections** Mild to moderate skin or skin structure infections caused by Streptococcus pyogenes or Staphylococcus aureus may be treated with erythromycin, however, resistant staphylococcal organisms may emerge.[L7261] Erythromycin can also be used to treat erythrasma, an infectious condition caused by Corynebacterium minutissimum.[L7261] **Gastrointestinal infections** Intestinal amebiasis caused by Entamoeba histolytica can be treated with oral erythromycin. Extraenteric amebiasis warrants treatment with other antimicrobial drugs.[L7261] **Genital infections/STIs** Erythromycin can be used as an alternative drug in treating acute pelvic inflammatory disease caused by N. gonorrheae in female patients who have demonstrated hypersensitivity or intolerance to penicillin.[L7261] Syphilis, caused by Treponema pallidum, can be treated with erythromycin. It serves as an alternative treatment for primary syphilis in patients who have demonstrated penicillin hypersensitivity. Erythromycin can also be used in the primary stage of primary syphilis.[L7261] Another approved indication of erythromycin is to treat chlamydial infections that cause conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections occurring in pregnancy. It is indicated as an alternative option to tetracyclines for the treatment of uncomplicated rectal, urethral and endocervical infections in adults caused by Chlamydia trachomatis.[L7261] Erythromycin can be used in nongonococcal urethritis can be used when tetracyclines cannot be administered. Finally, erythromycin is indicated to treat nongonococcal urethritis due to Ureaplasma urealyticum.[L7261] DB00199
6 Streptomycin For the treatment of tuberculosis. May also be used in combination with other drugs to treat tularemia (Francisella tularensis), plague (Yersia pestis), severe M. avium complex, brucellosis, and enterococcal endocarditis (e.g. E. faecalis, E. faecium). DB01082
7 Sulfadiazine For the treatment of rheumatic fever and meningococcal meningitis DB00359
8 Tetracycline Used to treat bacterial infections such as Rocky Mountain spotted fever, typhus fever, tick fevers, Q fever, rickettsialpox and Brill-Zinsser disease. May be used to treat infections caused by Chlamydiae spp., B. burgdorferi (Lyme disease), and upper respiratory infections caused by typical (S. pneumoniae, H. influenzae, and M. catarrhalis) and atypical organisms (C. pneumoniae, M. pneumoniae, L. pneumophila). May also be used to treat acne. Tetracycline may be an alternative drug for people who are allergic to penicillin. DB00759

Drugs for Chancroid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acyclovir Approved Phase 2, Phase 3 59277-89-3 2022
2 Anti-Infective Agents Phase 2, Phase 3
3 Antiviral Agents Phase 2, Phase 3

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Impact of Episodic Acyclovir Therapy on Ulcer Duration and HIV Shedding From Genital Ulcers Among Men in South Africa Completed NCT00164424 Phase 2, Phase 3 Acyclovir

Search NIH Clinical Center for Chancroid

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acetyl sulfisoxazole
Azithromycin
Ceftriaxone
Doxycycline
Erythromycin
ERYTHROMYCIN PWDR
Streptomycin
Sulfadiazine
Tetracycline

Cochrane evidence based reviews: chancroid

Genetic Tests for Chancroid

Anatomical Context for Chancroid

MalaCards organs/tissues related to Chancroid:

41
Skin, Lymph Node, Testes, T Cells, Cervix, Neutrophil, Endothelial

Publications for Chancroid

Articles related to Chancroid:

(show top 50) (show all 804)
# Title Authors PMID Year
1
Characterization of Haemophilus ducreyi cdtA, cdtB, and cdtC mutants in in vitro and in vivo systems. 9 38
11500438 2001
2
A Class I Haemophilus ducreyi Strain Containing a Class II hgbA Allele Is Partially Attenuated in Humans: Implications for HgbA Vaccine Efficacy Trials. 38
31036601 2019
3
Determination of an Interaction Network between an Extracellular Bacterial Pathogen and the Human Host. 38
31213562 2019
4
Genital Ulcer Disease: A Review of Pathogenesis and Clinical Features. 38
31253050 2019
5
Common Bacterial and Viral Infections: Review of Management in the Pregnant Patient. 38
30556401 2019
6
[Sexually Transmitted Infections in the Tropics]. 38
30324430 2018
7
First reported case of chancroid in the Czech Republic. 38
29749871 2018
8
Disease Pattern among Sexually Transmitted Infection Clinic Attendees: A Hospital-Based Study. 38
30504980 2018
9
From in vivo to in vitro: How the Guatemala STD Experiments Transformed Bodies Into Biospecimens. 38
29652094 2018
10
Putative vaccine candidates and drug targets identified by reverse vaccinology and subtractive genomics approaches to control Haemophilus ducreyi, the causative agent of chancroid. 38
29792307 2018
11
Direct Whole-Genome Sequencing of Cutaneous Strains of Haemophilus ducreyi. 38
29553314 2018
12
The Etiology of Genital Ulcer Disease and Coinfections With Chlamydia trachomatis and Neisseria gonorrhoeae in Zimbabwe: Results From the Zimbabwe STI Etiology Study. 38
29240636 2018
13
Despite Being "Known, Highly Promiscuous and Active": Presumed Heterosexuality in the USPHS's STD Inoculation Study, 1946-48. 38
30274528 2018
14
Macrolides for treatment of Haemophilus ducreyi infection in sexually active adults. 38
29226307 2017
15
Usefulness and Utility of NACO Regime in the Management of Sexually Transmitted Infections: A Pilot Study. 38
29263538 2017
16
Skin diseases of the vulva: Infectious diseases. 38
28397528 2017
17
Sexually Transmitted Infections in Melbourne, Australia from 1918 to 2016: nearly a century of data. 38
29720070 2017
18
Pseudoepitheliomatous hyperplasia causing a painful plaque in a HIV-infected female. 38
28470128 2017
19
2017 European guideline for the management of chancroid. 38
28081686 2017
20
Gonorrhoea in Greenland, incidence and previous preventive measures: a review to improve future strategies. 38
28745556 2017
21
Haemophilus ducreyi Cutaneous Ulcer Strains Diverged from Both Class I and Class II Genital Ulcer Strains: Implications for Epidemiological Studies. 38
28027326 2016
22
Sexually Transmitted Infections Among Hospitalized Patients With Human Immunodeficiency Virus Infection and Acquired Immune Deficiency Syndrome (HIV/AIDS) in Zahedan, Southeastern Iran. 38
27818966 2016
23
Sexually transmitted infections case notification rates in the Kingdom of Saudi Arabia, 2005-2012. 38
27580336 2016
24
Other sexually transmitted diseases chancroid and donovanosis. 38
27107782 2016
25
First case of chancroid in 14 years at the largest STI clinic in Paris, France. 38
26378189 2016
26
Complete Genome Sequences of 11 Haemophilus ducreyi Isolates from Children with Cutaneous Lesions in Vanuatu and Ghana. 38
27389258 2016
27
Haemophilus ducreyi Seeks Alternative Carbon Sources and Adapts to Nutrient Stress and Anaerobiosis during Experimental Infection of Human Volunteers. 38
26930707 2016
28
Haemophilus ducreyi: from sexually transmitted infection to skin ulcer pathogen. 38
26658654 2016
29
Prevalence of Sexually Transmitted Infection in Teenage Pregnancy in Rajavithi Hospital, Thailand. 38
27266230 2016
30
Medical Examination of Aliens--Revisions to Medical Screening Process. Final rule. 38
26812891 2016
31
Defining Potential Vaccine Targets of Haemophilus ducreyi Trimeric Autotransporter Adhesin DsrA. 38
25897604 2015
32
A case of syphilitic anal condylomata lata mimicking malignancy. 38
26555060 2015
33
[Male circumcision from an infectiological point of view]. 38
25492382 2015
34
Travel-related sexually transmitted infections. 38
26726895 2015
35
Molecular phylogenetic analysis of non-sexually transmitted strains of Haemophilus ducreyi. 38
25774793 2015
36
Pattern of sexually transmitted infections in a Muslim majority region of North India. 38
26392651 2015
37
Male Circumcision and STI Acquisition in Britain: Evidence from a National Probability Sample Survey. 38
26083250 2015
38
UK National Guideline for the management of Chancroid 2014. 38
25080286 2014
39
Haemophilus ducreyi RpoE and CpxRA appear to play distinct yet complementary roles in regulation of envelope-related functions. 38
25201944 2014
40
Syphilis and human experimentation from World War II to the present: a historical perspective and reflections on ethics. 38
24461955 2014
41
Pattern of sexually transmitted diseases in patients presenting at Ayub teaching hospital, Abbottabad. 38
25672192 2014
42
Chancroid - desperate patient makes own diagnosis. 38
24535694 2014
43
A (p)ppGpp-null mutant of Haemophilus ducreyi is partially attenuated in humans due to multiple conflicting phenotypes. 38
24914217 2014
44
Outer membrane protein P4 is not required for virulence in the human challenge model of Haemophilus ducreyi infection. 38
24961160 2014
45
Sexually transmitted infections. 38
24889293 2014
46
Epidemiology, clinical features, diagnosis and treatment of Haemophilus ducreyi - a disappearing pathogen? 38
24597521 2014
47
The Haemophilus ducreyi trimeric autotransporter adhesin DsrA protects against an experimental infection in the swine model of chancroid. 38
24844153 2014
48
Assessing the antibiotic potential of essential oils against Haemophilus ducreyi. 38
24885682 2014
49
Sexual transmission of human T-cell lymphotropic virus type 1. 38
25075475 2014
50
The Haemophilus ducreyi LspA1 protein inhibits phagocytosis by using a new mechanism involving activation of C-terminal Src kinase. 38
24902122 2014

Variations for Chancroid

Expression for Chancroid

Search GEO for disease gene expression data for Chancroid.

Pathways for Chancroid

Pathways related to Chancroid according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.02 CD4 CD36
2 10.61 CD4 CD36

GO Terms for Chancroid

Cellular components related to Chancroid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial matrix GO:0005759 9.13 HSPE1 HSPD1 DLAT
2 membrane raft GO:0045121 8.62 CD4 CD36

Biological processes related to Chancroid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.43 CD4 CD36
2 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.4 HSPE1 HSPD1
3 response to unfolded protein GO:0006986 9.37 HSPE1 HSPD1
4 positive regulation of interleukin-6 production GO:0032755 9.32 HSPD1 CD36
5 T cell activation GO:0042110 9.26 HSPD1 CD4
6 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.16 HSPD1 CD36
7 positive regulation of interleukin-12 production GO:0032735 8.96 HSPD1 CD36
8 positive regulation of T cell activation GO:0050870 8.62 HSPD1 CD4

Molecular functions related to Chancroid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA binding GO:0003723 9.46 WT1 RPL31 HSPE1 HSPD1
2 chaperone binding GO:0051087 8.96 HSPE1 HSPD1
3 high-density lipoprotein particle binding GO:0008035 8.62 HSPD1 CD36

Sources for Chancroid

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....